Trials / Completed
CompletedNCT00148395
Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 280 (planned)
- Sponsor
- Aktion Bronchialkarzinom e.V. · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study wants to assess different intensive therapy sequences for the treatment of non-small-cell lung cancer. It claims less on the efficacy of different chemotherapy combinations, than more on the comparison of different strategies of sequential single-agent, sequential double-agent or sequential triple-agent therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine | |
| DRUG | Navelbine | |
| DRUG | Carboplatin | |
| DRUG | Cisplatin | |
| DRUG | Mitomycin | |
| DRUG | Ifosfamide |
Timeline
- Start date
- 2002-06-01
- Completion
- 2008-04-01
- First posted
- 2005-09-08
- Last updated
- 2008-04-22
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00148395. Inclusion in this directory is not an endorsement.